Syros announces voluntary delisting from nasdaq and sec deregistration

Cambridge, mass.--(business wire)--syros pharmaceuticals, inc. (nasdaq:syrs) (the “company”) today announced that its board of directors (the “board”) has approved and the company intends to proceed with the voluntary delisting of its common stock from the nasdaq stock market (“nasdaq”) and the deregistration of its common stock in order to terminate and suspend the company's reporting obligations under the securities and exchange act of 1934, as amended (the "exchange act"). the company today.
NDAQ Ratings Summary
NDAQ Quant Ranking